T6	Treat-Disorder 23 66	relapsing-remitting multiple sclerosis (MS)
T8	Effect 77 124	primary central nervous system lymphoma (PCNSL)
T9	Treatment 147 182	21 doses of natalizumab monotherapy
T10	Age 2 13	40-year-old
T11	Gender 14 17	man
T12	Dosage 147 155	21 doses
T13	Drug 159 170	natalizumab
T5	Subject 2 66	40-year-old man with relapsing-remitting multiple sclerosis (MS)
T7	Adverse_event 67 76	developed
E1	Adverse_event:T7